Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 894416 in Healthy Males
NCT03315936Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 894416 in asthma (10 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events in SRD Part up to 17 days. Started Nov 2017; status: completed.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03315936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315936.